Clinical trial

Sex Differences in the Dilatory Response of Compound 21

Name
202206519
Description
When blood pressure changes, Angiotensin II is produced and released into the bloodstream. This substance can make blood vessels smaller (i.e., vasoconstriction) by acting through Angiotensin II type I receptors (AT1R) to increase blood pressure. Or it can increase the diameter of vessels (i.e., vasodilation) through Angiotensin II type II receptors (AT2R) to decrease blood pressure. These two receptors normally work in balance to maintain blood pressure. However, excess Angiotensin II released in the bloodstream may reduce the sensitivity of AT2Rs, leading to excessive activation of AT1Rs. This results in increased constriction which plays a major role in diseases such as high blood pressure, hardening of the arteries, and heart failure. In the body, Angiotensin II production is reduced in the presence of estrogen, as seen in pre-menopausal women. Pre-menopausal women have a greater protection against cardiovascular diseases compared to age-matched males, likely due to the protective effects of estrogen. However, the extent that estrogen may impact the sensitivity of Angiotensin II receptors in pre-menopausal is unknown. In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents), the blood vessels in a dime-sized area of the skin are studied in healthy young women and men. As a compliment to these measurements, blood is drawn from the subjects and circulating factors that may contribute to cardiovascular health are measured.
Trial arms
Trial start
2022-10-03
Estimated PCD
2023-04-01
Trial end
2023-10-01
Status
Active (not recruiting)
Phase
Early phase I
Treatment
Compound 21
Compound 21 + Ringer's is perfused at 10 doses increasing serially for 10 minutes each from 10\^-12 M to 10\^-3 M
Arms:
Local lactated Ringer's (control) perfusion
Compound 21 + losartan
Compound 21 + losartan (43 µM) is perfused at 10 doses increasing serially for 10 minutes each from 10\^-12 M to 10\^-3 M.
Arms:
Local losartan perfusion
Size
24
Primary endpoint
Microvascular AT2R sensitivity following local control treatment
post 1 hour of local control treatment
Microvascular AT2R sensitivity following local AT1R inhibition
post 1 hour of local losartan treatment
Eligibility criteria
Inclusion Criteria: * Young women or men, * 18-35 years old, * Body mass index between 18 and 30 kg/m2, * Systolic blood pressure \<140, * Diastolic blood pressure \<90 mmHg. Exclusion Criteria: * Skin allergies, skin disorders, or skin diseases such as Raynaud's phenomenon or other history of cold intolerance, * History of metabolic or cardiovascular disease, * Taking medications that could alter vascular function, including antidepressants, anxiety medications, or cholesterol or blood pressure lowering drugs, * Women with oligo- or amenorrhea, * Women that are pregnant or nursing * current tobacco use, * Allergy to materials used during the experiment (e.g. latex).
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['EARLY_PHASE1'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'BASIC_SCIENCE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 24, 'type': 'ACTUAL'}}
Updated at
2023-09-14

1 organization

Organization
Anna Stanhewicz